相关实验视频

Updated: Jul 13, 2025

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Discovery of Driver Genes in Colorectal HT29-derived Cancer Stem-Like Tumorspheres

Published on: July 22, 2020

通过使用综合生物信息学分析,确定ACHE作为针对非小细胞肺癌 (NSCLC) 相关的索拉索宁的枢纽基因

Tong Liu^1,2, Boke Zhang³, Yating Gao³

¹Anhui University of Chinese Medicine, Hefei, Anhui, China.

|October 16, 2023

概括

索拉索宁是一种来自Solanum nigrum的化合物,通过向乙胆化酶 (ACHE) 来诱导非小细胞肺癌 (NSCLC) 的亡并减少炎症. 这项研究确定ACHE是NSCLC治疗中索拉索宁的关键治疗标.

科学领域:

药理学药理学是指药理学的学科.
在瘤学瘤学.
生物化学生物化学

背景情况:

索拉索宁是Solanum nigrum L.的一个关键成分,具有抗癌性质.
索拉松因在非小细胞肺癌 (NSCLC) 中的精确生物标和机制在很大程度上仍未明确.

研究的目的:

为了识别NSCLC中索拉索宁的分子标.
阐明索拉因发挥抗癌作用的机制,重点关注亡和炎症.

主要方法:

转录组数据分析和人工智能驱动的目标预测确定了乙胆酶 (ACHE) 作为潜在的目标.
使用A549细胞的体外研究评估了索拉松因对细胞活力,细胞亡标志物 (Bcl-2/Bax,切割caspase-3) 和炎症通路 (p38 MAPK,IL-1β,TNF-α) 的影响.
用分子对接和动力学模拟来验证索拉索宁-ACHE相互作用.

主要成果:

遗传依赖性分析和分子对接证实ACHE是索拉索宁的主要点.
索拉索宁治疗显著抑制了A549细胞活力,降低了Bcl-2/Bax比率,并上调了分离的caspase-3表达,表明了亡诱导.
索拉索宁通过抑制p38 MAPK信号来抑制炎症反应,由降低IL-1β和TNF-α水平证明.

结论:

索拉索宁有效诱导细胞亡,并在NSCLC细胞中发挥抗炎作用.
这项研究确立了乙胆化酶 (ACHE) 作为索拉松因在NSCLC中的治疗作用的关键分子标.

关键词:

亚希亚是什么意思?亚希亚是什么意思抗炎药物抗炎药物抗炎药物细胞灭亡 (apoptosis) 是一种死亡的过程.生物信息学是一种生物信息学.索拉索尼因 (Solasonine) 是一种可靠的药物.

更多相关视频

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Author Spotlight: Advancements in Molecular Biomarker Testing for Non-Squamous Non-Small Cell Lung Cancer

Published on: September 8, 2023

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

HOX Loci Focused CRISPR/sgRNA Library Screening Identifying Critical CTCF Boundaries

Published on: March 31, 2019

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

lncRNA - Long Non-coding RNAs

lncRNA - Long Non-coding RNAs

In humans, more than 80% of the genome gets transcribed. However, only around 2% of the genome codes for proteins. The remaining part produces non-coding RNAs which includes ribosomal RNAs, transfer RNAs, telomerase RNAs, and regulatory RNAs, among other types. A large number of regulatory non-coding RNAs have been classified into two groups depending upon their length – small non-coding RNAs, such as microRNA, which are less than 200 nucleotides in length, and long non-coding RNA...

Cancer-Critical Genes II: Tumor Suppressor Genes

Cancer-Critical Genes II: Tumor Suppressor Genes

Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...